Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) axis have transformed cancer therapy, yet reliable biomarkers for accurately predicting therapeutic benefit remain limited. Peripheral blood biomarkers have emerged as attractive candidates because of...
Xue-Jun Guo, Yan-Hui Wei, Zhao-Xu Miao et al.· Frontiers in Immunology· 1 citation
A context-dependent framework integrating macrophage heterogeneity, immunometabolism, spatial biology, biomarker development, and therapeutic decision-making to advance precision immunotherapy is proposed.
Xue-Jun Guo, Jing-Ya Yu, Xiao-Yan Lin et al.· Critical reviews in oncology...· 1 citation
It is concluded that targeting tumor immunosenescence represents a promising but incompletely validated therapeutic axis for enhancing anti-tumor immunity in breast cancer.
Qing Lei, Xue-Jun Guo· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.